Psychedelics & Empathogens in 2026
Psilocybin for AUD. Ibogaine for OUD. MDMA's setback. What the clinical trial landscape actually shows.
Body — 8 lenses: [Science: 5-HT2A agonism (classical psychedelics), MDMA serotonin/dopamine/NE release, ibogaine multi-receptor (anti-addiction window). Biology: acute autonomic effects, serotonin syndrome risk in combos, ibogaine cardiac risk (QT prolongation — real, requires screening), HPPD rare but possible. Psychology: “mystical experience” correlating with therapeutic outcome (Griffiths et al.); challenging experiences and how they’re handled in set/setting. Policy: mostly Schedule I; Oregon Measure 109, Colorado Prop 122, FDA breakthrough designations; MDMA 2024 rejection; state-level initiatives for decrim/regulated access. Trends: psychedelic clinic growth (often off-label ketamine), “microdosing” research (mostly null), ayahuasca tourism. Social: counterculture roots → medicalization → commercialization tension; indigenous reciprocity conversation. Treatment: psilocybin+therapy for AUD (NYU + Hopkins RCTs); ibogaine for OUD (Stanford case series, Kentucky state research); MDMA-AT for PTSD (post-2024 setback, new trials). Harm reduction: set/setting, integration, contraindications (SSRIs, heart conditions, family psychosis history for classical psychedelics), test kits.]
Sources Cited
- 01.Ahttps://heal.nih.govNIH HEAL
- 02.Ahttps://clinicaltrials.govClinicalTrials.gov
- 03.B
Filed Under
sciencebiologypsychologypolicytrendssocial-culturaltreatmentharm-reductionPeer-Reviewed Research
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
The Ozempic-for-Drinking Trial Just Published Real Numbers. The Headline Effect Missed Its Own Primary Target.
A Phase 2 trial of oral semaglutide for alcohol use disorder found real reductions in heavy drinking days and craving — but missed its own pre-registered primary endpoint. Here's what that gap means, and why the VA is running the next version now.
Science & Medicine45 Million Americans Have a Substance Use Disorder Right Now. The Government's Own Survey Says So — and Says Most Won't Get Treated.
SAMHSA's 2025 NSDUH shows 45 million Americans met SUD criteria in the past year — 15.3% of everyone 12 and older. Here's what the numbers actually say.
Science & MedicineNicotine Pouches Didn't Slip Past Public Health. They Got Rebranded as Self-Optimization
Nicotine pouch shipments grew 37% in a year almost entirely outside the frame most youth-prevention conversations are still having. Here's how gym-bro TikTok culture, not tobacco advertising, built that growth.